X4 Pharmaceuticals, Inc. (XFOR)
Nasdaq: XFOR · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2010
Who owns X4 Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
11
Morgan Stanley holds 10.2% of Common Stock, as its SCHEDULE 13G/A filed Mar 6, 2026 says.
Directors and officers
8
report now, of 36 people on the record since 2017. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 11 named at left.
Holders of 5% or moreshare of the class, as filed
Morgan Stanley
SCHEDULE 13G/A · filed Mar 6, 2026 · Common Stock · 9.4% in Feb 12, 2026
Empery Asset Management, LP
SCHEDULE 13G/A · filed Jan 15, 2026 · Common Stock, $0.001 par value per share · 9.99% in Oct 21, 2025
Coastlands Capital LP
SCHEDULE 13G · filed Oct 3, 2025 · Common Stock, par value $0.001 per share · 9.99% in Aug 18, 2025
Deep Track Capital, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · 9.99% in Aug 19, 2025
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · 7.3% in May 15, 2026
BCLS II Equity Opportunities, LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.001 per share · 9.99% in Sep 15, 2025
Saturn V Capital Management LP
SCHEDULE 13G · filed Feb 17, 2026 · Common Stock
Growth Equity Opportunities 18 VGE, LLC
SCHEDULE 13D/A · filed Oct 29, 2025 · Common Stock, par value $0.001 per share · 9.99% in Aug 15, 2025
Blackrock, Inc.
SCHEDULE 13G · filed Jul 30, 2026 · Common Stock · 3% in Jul 18, 2025
Trails Edge Capital Partners, LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.001 per share · 9.9% in Aug 18, 2025
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G · filed Sep 21, 2026 · Common Stock, $0.001 par value per share
The Vanguard Group
SCHEDULE 13G/A · filed Jan 31, 2025 · Common Stock · reported falling below 5%
Fmr LLC
SCHEDULE 13G/A · filed Oct 7, 2026 · COMMON STOCK · reported falling below 5%, from 9.7% in Feb 5, 2026
Bvf Partners L P/il
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 9.9% in Aug 20, 2025
Nantahala Capital Management, LLC
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 9.99% in Nov 14, 2025
Orbimed Advisors LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
What XFOR reports owning in othersstakes of 5% or more, and other ties
X4 Pharmaceuticals, Inc. reports no stake in another company in the record.
Insider tradesForm 4
5sales
2purchases
0sales on a scheduled plan
3people selling
$500,000sold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Oct 19, 2025 to Oct 19, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 19, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 56 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Craig Adam R | Executive Chairman | 1 | $200,000 | 0 | 2 | $300,000 |
| Volpone John | President | 1 | $100,000 | 0 | 0 | $0 |
| Kirske David | Chief Financial Officer | 3 | $100,000 | 0 | 0 | $0 |